BRAIN Biotech AG: BRAIN actively supports the UN Global Compact
DGAP-News: BRAIN Biotech AG
/ Key word(s): Sustainability
Zwingenberg, Germany, June 8, 2021
BRAIN Biotech AG, Germany, now actively supports the UN Global Compact, a voluntary initiative based on company commitments to implement universal sustainability principles and to advance United Nations goals such as the Sustainable Development Goals (SDGs). With our current products and solutions, we already directly address at least five UN sustainability goals.
BRAIN Biotech AG (BRAIN, ISIN DE0005203947 / WKN 520394) now atively supports the UN Global Compact with its corporate responsibility initiative and principles. By joining the UN Global Compact, BRAIN now formally commits to the values of the world's largest initiative for corporate social responsibility and thus commits to ten universal principles concerning human rights, labour standards, environment and climate as well as the prevention of corruption.
With the current products and solutions, BRAIN already directly addresses at least five of the UN Sustainable Development Goals (SDG):
Adriaan Moelker, CEO BRAIN Biotech AG, states: "We take pride to support the UN Global Compact, one of the globally most important initiatives for the corporate sector to adopt sustainable and socially responsible policies. BRAIN develops products and services, which change the way industrial production is done. Our natural and sustainable bio-based processes accelerate the economic transformation to a circular economy. In addition, we incorporate sustainability aspects and good corporate governance in the daily management of our operations. Acting responsibly is elementary for all of BRAIN's stakeholders so that I am personally heading our ESG initiatives. We are currently preparing a corporate sustainability report to document our goals and their implementation also under the framework of the UN Global Compact."
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management.
Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors.
BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.
BRAIN Biotech AG ("BRAIN") is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group's business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company's own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.
The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.
Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).
About UN Global Compact
The United Nations Global Compact is a non-binding United Nations pact to encourage businesses and firms worldwide to adopt sustainable and socially responsible policies, and to report on their implementation. The UN Global Compact is a principle-based framework for businesses, stating ten principles in the areas of human rights, labor, the environment and anti-corruption. Under the Global Compact, companies are brought together with UN agencies, labor groups and civil society. Cities can join the Global Compact through the Cities Programme.
Further details at:
Contact Investor Relations
Follow BRAIN Biotech on Twitter (@BRAINbiotech) and on LinkedIn (@BRAIN AG)
08.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Company:||BRAIN Biotech AG|
|Darmstädter Straße 34-36|
|Phone:||+49 (0) 62 51 / 9331-0|
|Fax:||+49 (0) 62 51 / 9331-11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1205443|
|End of News||DGAP News Service|